Leadless Pacemaker Fixation Mechanisms 2026 — PatSnap Eureka
Leadless Pacemaker Fixation Mechanisms 2026
Fixation mechanisms are the pivotal determinant of leadless cardiac pacemaker safety, pacing stability, and retrievability. This dataset snapshot covers filings from 7 assignees across US, EP, and WO jurisdictions from 2010 to 2026.
Fixation Engineering at the Heart of Leadless Pacing
Leadless cardiac pacemakers eliminate transvenous leads and subcutaneous pulse generator pockets in favor of miniaturized, self-contained intracardiac devices. In this dataset, three principal fixation paradigms are identifiable: passive tine-based fixation using nitinol or polymer tines, active helix/screw fixation rotated into the endocardium, and radial fixation where hooks or protrusions penetrate the endocardium radially from the device body.
A fourth emerging dimension is electronic fixation stability monitoring — embedded algorithms and sensor suites that continuously assess whether the device remains adequately anchored. Medtronic’s IMD stability monitor architecture, filed in 2013 and granted across US, WO, and EP jurisdictions, uses impedance electrodes and accelerometers to detect mechanical motion, distinguish therapy-grade fixation from partial dislodgement, and wirelessly transmit stability flags to external programmers.
Clinical literature consistently identifies dislodgement, elevated pacing thresholds, and pericardial effusion as the principal complications linked to fixation performance. The fixation mechanism is tightly coupled to delivery system design, retrieval feasibility, and long-term pacing threshold stability. Fibrosis around tine and helix fixation elements increases extraction difficulty over time, driving Biotronik’s 2020–2025 temporary pacing family with engineered retrieval.
In this dataset, innovation is moderately concentrated: three assignees — Pacesetter/Abbott, Biotronik, and Cardiac Pacemakers/Boston Scientific — account for approximately 65% of patent records in retrieved records. Medtronic’s filings focus on the electronic stability monitoring sub-domain rather than novel mechanical fixation geometries, reflecting strategic IP positioning around performance assurance rather than physical anchoring.
Filing Trends and Technology Cluster Distribution
In this dataset, filings span 2010 to 2026 across four identifiable technology clusters: passive tine fixation, radial active fixation, active helix fixation, and electronic stability monitoring. The two charts below profile the distribution of filings by technology cluster and the chronological filing trajectory.
Patent Distribution by Technology Cluster — Leadless Pacemaker Fixation (Dataset Snapshot)
Radial active fixation and electronic stability monitoring together account for the largest share of patent records in this dataset, reflecting competitive activity from Pacesetter/Abbott, Biotronik, and Medtronic across those sub-domains.
↗ Click bars to exploreFiling Activity by Phase — Leadless Pacemaker Fixation, 2010–2026 (Dataset Snapshot)
Filing activity in this dataset shows a clear escalation from the foundational 2010–2013 phase through competitive expansion in 2014–2017, with the most recent 2018–2026 phase introducing Chinese market entries, temporary pacing, and AI-guided implantation filings.
↗ Click bars to exploreClinical Deployment Contexts for Leadless Pacemaker Fixation
In this dataset, fixation mechanism patents and clinical literature are distributed across five distinct cardiac application domains, each imposing specific mechanical, anatomical, and procedural demands on the fixation approach.
Right Ventricular Single-Chamber Pacing
The primary and most mature application domain, targeting patients with bradyarrhythmia, atrial fibrillation with slow ventricular response, and AV block. A 2021 systematic review and meta-analysis assessed safety and efficacy of leadless pacemakers in this setting, where dislodgement, elevated pacing threshold, and pericardial effusion are the principal reported adverse events. The Micra (Medtronic, passive tines) and Nanostim (Abbott, active helix) platforms are positioned exclusively in this domain.
Active FixationHis Bundle Conduction System Pacing
Cardiac Pacemakers, Inc. filed US patents in 2019 and 2021 describing an LCP configured for atrial placement to pace the bundle of His, requiring anchoring in a specific atrioventricular septal corridor. Biotronik filed corresponding EP (2020) and US (2023) patents for His bundle pacing LCP, indicating competitive activity. This represents the most technically demanding fixation challenge in the dataset: the anatomical target is small, the tissue interface is fibrous, and clinical outcomes are highly sensitive to micro-positional stability.
Conduction SystemCardiac Resynchronization Therapy CRT
The WiSE-CRT system (EBR Systems) delivers leadless LV endocardial stimulation using an ultrasound-powered receiver electrode fixed to the LV endocardium. Clinical literature documents European first-in-human experience with the combination of Micra + WiSE-CRT (2020), where the LV electrode’s fixation relative to subcutaneous ICD sensing is anatomically critical. A 2020 porcine model study also demonstrated synchronized biventricular pacing using wirelessly powered leadless pacemakers.
Biventricular PacingTemporary Pacing Bridge Applications
Biotronik filed a dedicated temporary implantable leadless pacemaker patent family spanning WO 2021, US 2021/2023/2025, and EP 2023, featuring an indwelling retrieval mechanism (IRM) for planned short-term dwell and guaranteed removal. This addresses post-extraction bridging needs in pacemaker-dependent patients without the infection and mobility risks of conventional transvenous temporary leads. Fixation is engineered from the outset for retrieval, directly responding to evidence that chronic tissue ingrowth around tine and helix elements increases extraction risk.
Temporary ImplantLeading Assignees in Leadless Pacemaker Fixation — Dataset Snapshot
In this dataset, 7 distinct assignees account for all retrieved patent records, with Pacesetter, Inc. (Abbott) holding the largest filing count at 9 patents in retrieved records. Three assignees — Pacesetter/Abbott, Biotronik, and Cardiac Pacemakers/Boston Scientific — together account for approximately 65% of patent records in this dataset.
Top Assignees by Filing Count — Leadless Pacemaker Fixation (Dataset Snapshot)
↗ Click bars to explorePacesetter, Inc. (Abbott)
Pacesetter holds the largest filing count in this dataset at 9 patents spanning US, EP, and WO jurisdictions from 2012 to 2026 (pending). Their portfolio covers radial hook-based fixation — with core claims active from 2012 specifying fixation achievable in fewer than two device rotations — as well as attachment feature refinements (2019 WO, 2021 US) and a 2026 US pending application for AI model-guided implant site selection using real-time impedance data. Multiple radial fixation patents are in active grant status across US and EP jurisdictions.
United StatesBiotronik SE & Co. KG
Biotronik holds 8 patents in this dataset across US, EP, and WO jurisdictions, spanning 2014 to 2025. Their portfolio encompasses radial fixation for conventional leadless pacing (US 2014, EP 2014–2015), a modified implantation tool tip for tine-anchor optimization (EP 2019), His bundle pacing LCP configurations (EP 2020, US 2023), and a dedicated temporary implantable leadless pacemaker family (WO 2021, US 2021/2023/2025, EP 2023) featuring an indwelling retrieval mechanism. Patents span active and pending statuses across multiple jurisdictions.
Germany — DENext-Generation Fixation Concepts Shaping the Field Through 2026
The most recent filings in this dataset — spanning 2020 to 2026 — signal four forward-edge directions: AI-guided intraoperative implant site selection, engineered-retrieval temporary fixation, conduction system pacing fixation, and modular multi-device fixation coordination.
AI Model-Guided Implant Site Selection (2026)
The most recent pending filing in this dataset — Pacesetter, Inc. (2026, US pending) — describes a system that receives multi-parameter data from the leadless pacemaker during delivery, including pacing impedance plus additional measurements, and feeds this into a pre-trained model built from historical patient implant data to output a site-appropriateness recommendation. This is the first filing in this dataset to explicitly couple machine learning to intraoperative fixation decision support. It represents a competitive frontier that is orthogonal to existing mechanical anchor claim landscapes.
Engineered-Retrieval Temporary Leadless Pacing (2020–2025)
Biotronik’s temporary pacing patent family (WO 2021, US 2021/2023/2025, EP 2023) reflects a design philosophy where fixation is engineered from the outset for planned short-term dwell and guaranteed retrieval via an indwelling retrieval mechanism (IRM). This directly responds to clinical evidence that chronic tissue ingrowth into tine or helix fixation elements creates retrieval risk years after implant. The family addresses post-extraction bridging for pacemaker-dependent patients without the infection and mobility risks of conventional transvenous temporary leads.
Passive Tine vs. Radial Active Fixation — Key Dimensions
Click any row to explore further.
| Dimension | Passive Tine Fixation | Radial Active Fixation |
|---|---|---|
| Mechanism | Flexible nitinol or polymer tines engage myocardial trabeculae passively upon deployment | Hooks or protrusions penetrate the endocardium radially from the device body |
| Rotations Required | None — passive engagement; no device rotation needed | Achievable in fewer than two device rotations per Pacesetter/Biotronik patent claims |
| Fixation Element Diameter | Tines extend outward; overall profile larger than device capsule | Constrained to be equal to or less than the outer diameter of the pacemaker capsule |
| Clinical Platform | Micra (Medtronic) — first-generation commercially deployed platform | Aveir VR (Abbott) helix; Biotronik radial hook family; MicroPort radial system |
| Retrieval Feasibility | Specialized snare techniques required; fibrosis increases extraction difficulty over time | Designed for fewer-rotation withdrawal; tissue ingrowth still a long-term risk |
| Key Patent Assignees | Medtronic (Micra platform); Biotronik (modified implantation tool, EP 2019); Pacesetter (attachment features, 2019–2021) | Pacesetter, Inc. (2012–2017, US and EP active); Biotronik SE & Co. KG (2014–2015, US and EP); MicroPort Soaring CRM (2020–2022, US and EP) |
| Pacing Threshold Behavior | Stable with trabecular entrapment; elevation associated with fibrosis progression | Thresholds improve with longer dwell after helix deployment per 2018 Nanostim clinical literature |
| His Bundle Pacing Suitability | Not described in dataset for His bundle applications | Active filings from Cardiac Pacemakers, Inc. (2019, 2021) and Biotronik (2020, 2023) for septal His bundle fixation |
Frequently Asked Questions — Leadless Pacemaker Fixation Mechanisms
In this dataset, three principal fixation paradigms are identifiable: (1) passive tine-based fixation, where flexible nitinol or polymer tines engage trabecular myocardial tissue upon deployment; (2) active helix/screw fixation, where a helical element is rotated into the endocardium; and (3) radial fixation, where hooks or protrusions penetrate the endocardium radially from the device body.
Pacesetter, Inc. (Abbott) holds the largest filing count in this dataset at 9 patents across US, EP, and WO jurisdictions from 2012 to 2026. Their portfolio covers radial hook-based fixation with core claims active from 2012, attachment feature refinements (2019 WO, 2021 US), and a 2026 US pending application for AI model-guided implant site selection using real-time pacing impedance data.
Radial active fixation uses hooks or protrusions that penetrate the endocardium radially, and per Pacesetter and Biotronik patent claims, this can be accomplished in fewer than two rotations of the device. Passive tine fixation requires no device rotation — flexible tines passively engage myocardial trabeculae upon deployment. The fixation element diameter in radial designs is constrained to be equal to or less than the outer diameter of the pacemaker, preserving compact cross-section through the delivery sheath.
Medtronic’s filings in this dataset are focused on electronic fixation stability monitoring rather than novel mechanical fixation geometries. Their IMD stability monitor architecture, filed in 2013 and granted across US, WO, and EP jurisdictions, uses impedance electrodes and accelerometers to detect mechanical motion of the device, distinguish therapy-grade fixation from partial dislodgement, and wirelessly transmit stability flags to external programmers.
MicroPort Soaring CRM (Shanghai) filed both US and EP patents for leadless pacemaker fixation systems (2020–2022), representing China’s strategic effort to establish IP positions in global markets rather than only domestic CN filings. Their filings describe interlocking tail-end and head-end component architectures with biodegradable connector elements, potentially enabling modular assembly and component upgrade within the cardiac chamber without full device retrieval.
Clinical literature in this dataset consistently identifies dislodgement, elevated pacing thresholds, and pericardial effusion as the principal complications linked to fixation performance. Among retrieved clinical literature, the single-chamber right ventricular pacing domain is the dominant setting for fixation-related adverse event reporting. Fibrosis around tine and helix fixation elements also increases extraction difficulty over time, which motivated Biotronik’s 2020–2025 temporary pacing family with an engineered indwelling retrieval mechanism.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.